Search our site 
Advanced Search
Home | Exam dates | Contact us | About us | Testimonials |

You are in Home >> Intensive Care >> Sepsis >> Metabolic & Cytokine Therapies >> Potential therapies: Literature

Abraham et al. The ADDRESS trial. NEJM 2005

Created: 21/5/2007
Updated: 21/5/2007


Abraham E, Laterre PF, Garg R et al.
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
N Engl J Med. 2005 29; 353(13):1332-41

Major finding

The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications (for every 30 patients given aPC one additional patient required a blood transfusion), indicates that Activated Protein C should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.

SiteSection: Article
  Posting rules

     To view or add comments you must be a registered user and login  

Login Status  

You are not currently logged in.
UK/Ireland Registration
Overseas Registration

  Forgot your password?

All rights reserved © 2021. Designed by AnaesthesiaUK.

{Site map} {Site disclaimer} {Privacy Policy} {Terms and conditions}

 Like us on Facebook